Guardian Pharmacy Services, Inc. filings document the reporting obligations of a NYSE-listed long-term care pharmacy services company with Class A common stock. Recent Form 8-K filings furnish operating results, financial guidance, investor presentation materials, and exhibits tied to the company’s pharmacy services business.
Proxy and current-report filings also cover board elections, advisory compensation votes, stockholder voting results, material stock purchase agreements, lock-up arrangements, and conversion-related disclosures involving Class A and Class B common stock. These records describe governance, ownership, capital-structure mechanics, registered securities, and matters linked to the company’s September 2024 corporate reorganization.
For Guardian Pharmacy Services, Inc. (GRDN), the issuer, the reporting persons collectively beneficially own 27,822,550 shares of Class A common stock, approximately 43.9% of the class. The reporting persons are Bindley Capital Partners I, LLC, William E. Bindley, Thomas J. Salentine, Jr., Pharmacy Investors, LLC, John Ackerman, Cardinal Equity Fund, L.P., Fred P. Burke, David K. Morris and G. Kendall Forbes.
Class A shares outstanding were 63,320,300 as of September 27, 2026; that day, 13,521,396 Class A shares were issued upon automatic conversion of an equal number of Class B shares. Thomas J. Salentine, Jr. directly owns 35,714 shares. David K. Morris’s reported holdings exclude 641,870 shares he agreed to transfer on or before November 11, 2026, under a September 2025 domestic relations order.
Guardian Pharmacy Services, Inc. director and Executive Vice President, Chief Operating Officer David K. Morris reported an automatic one-for-one conversion on September 27, 2026: 641,870 shares of Class B common stock converted into 641,870 shares of Class A common stock. He reported 896,341 shares of Class A common stock following the transaction, excluding 641,870 shares he had agreed to transfer on or before November 11, 2026, under a September 2025 domestic relations order.
Guardian Pharmacy Services, Inc. reported that Senior Vice President, Payor and Industry Strategy Chris Crisafulli's 18,931 shares of Class B common stock automatically converted into 18,931 shares of Class A common stock on September 27, 2026, on a one-for-one basis under its Amended and Restated Certificate of Incorporation. Crisafulli directly held 53,057 Class A shares following the conversion.
Guardian Pharmacy Services, Inc. reported that Senior Vice President, Sales Richard Eakins’s 36,052 shares of Class B common stock automatically converted into 36,052 shares of Class A common stock on September 27, 2026, on a one-for-one basis under the company’s Amended and Restated Certificate of Incorporation. After the conversion, he directly held 134,930 Class A shares and 0 Class B shares.
Guardian Pharmacy Services, Inc. (GRDN) reported that Cardinal Equity Fund, L.P., a member of its 10% owner Group, automatically converted 471,057 Class B shares into Class A common stock on September 27, 2026, on a one-for-one basis. After the conversion, Cardinal Equity Fund held 1,287,237 Class A shares and 0 Class B shares.
Guardian Pharmacy Services, Inc. reports that Bindley Capital Partners I, LLC, a member of its 10% owner group, had 6,100,175 shares of Class B common stock automatically converted into 6,100,175 shares of Class A common stock on September 27, 2026. The conversion occurred on a one-for-one basis under the company’s Amended and Restated Certificate of Incorporation. Bindley Capital Partners I, LLC reported holding 16,669,666 shares of Class A common stock after the conversion.
Guardian Pharmacy Services, Inc. (GRDN) officer Douglas Towns, identified as Senior Vice President, General Counsel, Senior Compliance Officer & Corporate Secretary, had 23,450 shares of Class B common stock automatically converted into 23,450 shares of Class A common stock on September 27, 2026, on a one-for-one basis under the issuer’s Amended and Restated Certificate of Incorporation. His reported direct position afterward was 113,006 Class A shares, with 0 Class B shares remaining.
Guardian Pharmacy Services, Inc. (GRDN) entered into lock-up agreements effective September 10, 2026 with its founders, executive officers and certain other employees covering their Class A common stock. After an automatic conversion of 13,521,396 shares of Class B common stock into Class A common stock on September 27, 2026, approximately 29.9 million shares of Class A common stock held by these holders will be subject to the lock-up.
The locked-up shares represent about 81% of roughly 37 million Class A shares that will be held by all founders, executive officers and other pre-IPO employees. Subject to limited exceptions and without the Company’s prior consent, these shares cannot be offered, sold, distributed, disposed of or transferred through September 14, 2027. Following the September 27, 2026 conversion, the Company will have 63,320,300 shares of Class A common stock outstanding.
Guardian Pharmacy Services, Inc. reported solid growth for the three and six months ended June 30, 2026. Q2 2026 revenue was $351,768 (in thousands), up 2.2% year over year, while net income attributable to the company rose to $21,872 (in thousands) from $9,030 (in thousands). Diluted EPS increased to $0.34 from $0.14. Adjusted EBITDA for Q2 grew to $29,658 (in thousands), or 8.4% of revenue.
Results were shaped by 2025 acquisitions and U.S. Inflation Reduction Act (IRA) drug pricing, which reduced organic revenue but more sharply lowered product costs, improving gross margin from 19.8% to 22.8%. Residents served increased from 195,000 to 210,000, and Q2 prescriptions dispensed rose from 7.0 million to 7.6 million.
The company recorded an $8.5 million cash gain from a payor-reimbursement settlement, boosting other income. Liquidity remained strong with $89,807 (in thousands) of cash and cash equivalents and no borrowings outstanding on a $40 million revolving credit facility that now matures in 2030, with the option to expand total capacity to $80 million.
Guardian Pharmacy Services reported Q2 2026 revenue of $351,768 thousand compared with $344,334 thousand a year earlier, as IRA‑related pricing reductions muted reported growth. Net income attributable to the company was $21,872 thousand, diluted EPS was $0.34, and Adjusted EBITDA was $29,658 thousand, or 8.4% of revenue. Results included an $8.5 million cash settlement related to a payor‑reimbursement matter, recorded in other income.
Cash and cash equivalents rose to $89,807 thousand at June 30, 2026, with total assets of $443,578 thousand. Based on year‑to‑date performance, management raised its 2026 outlook to revenue of $1.43 billion–$1.45 billion and Adjusted EBITDA of $129 million–$131 million, excluding future acquisitions. Guardian also acquired Wellness Concepts in Virginia, opened a greenfield pharmacy in Lexington, Kentucky, and implemented new COO/CFO appointments and a regional leadership structure.